US FDA approved the use of the use of Lumigan (bimatoprost ophthalmic solution), 0.01%, for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension on August 31, 2010.
Lumigan 0.01% is a once-daily prescription eye drop that provides effective and sustained IOP lowering.
Lumigan 0.01% will be available in the fourth quarter of 2010, and is the newest addition to Allergan's comprehensive glaucoma portfolio
Read more: http://www.drugs.com/newdrugs/allergan-inc-receives-fda-approval-lumigan-0-01-first-line-therapy-indicated-reduction-elevated-2283.html#ixzz0ypZpVPBW
No comments:
Post a Comment